Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06363370
PHASE3

Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections

Sponsor: Kexing Biopharm Co., Ltd.

View on ClinicalTrials.gov

Summary

To evaluate the efficacy and safety of interferon α1b (GB05) in the treatment of children under 2 years of age with respiratory syncytial virus infection.

Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Human Interferon α1b Inhaled Solution in the Treatment of Respiratory Syncytial Virus Lower Respiratory Tract Infection in Children.

Key Details

Gender

All

Age Range

2 Months - 2 Years

Study Type

INTERVENTIONAL

Enrollment

322

Start Date

2024-03-27

Completion Date

2026-06-30

Last Updated

2024-04-12

Healthy Volunteers

No

Interventions

DRUG

Human interferon α1b Inhalation Solution

Participants will receive Human interferon α1b Inhalation Solution

DRUG

Inhalation Solution Placebo

Participants will receive Inhalation Solution Placebo

Locations (1)

Children's Hospital, Capital Institute of Pediatrics

Beijing, Beijing Municipality, China